Baseline biomarkers associated with renal outcomes and landmark analysis for renal response, renal disease progression, and GDF-15 at 3 and 6 months
| . | Athens . | Pavia . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Renal stage | ||||||
| 1 | 1 | 1 | ||||
| 2 | 1.913 | 0.216-55 | .746 | 0.998 | 0.303-3.33 | .354 |
| 3 | 1.940 | 0.199-47 | .701 | 2.106 | 0.56-7.96 | .273 |
| GDF−15 >4000 pg/mL | 3.996 | 1.16-13.8 | .028 | 2.537 | 1.07-6.62 | .047 |
| . | Athens . | Pavia . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Renal stage | ||||||
| 1 | 1 | 1 | ||||
| 2 | 1.913 | 0.216-55 | .746 | 0.998 | 0.303-3.33 | .354 |
| 3 | 1.940 | 0.199-47 | .701 | 2.106 | 0.56-7.96 | .273 |
| GDF−15 >4000 pg/mL | 3.996 | 1.16-13.8 | .028 | 2.537 | 1.07-6.62 | .047 |